Assessing the effectiveness of software driven digital therapeutics in patients with coronary artery disease or post coronary intervention: real-world evidence study
DOI:
https://doi.org/10.18203/2349-3933.ijam20241015Keywords:
Cardiovascular health, CAD, Post-coronary interventions, Digital therapeutics, Blood pressure, Quality of lifeAbstract
Background: Coronary artery disease (CAD) is a significant health concern worldwide. Acute coronary syndrome (ACS) is a common form of CAD that requires immediate treatment. Digital therapeutics (DTx) have emerged as a promising field for disease management, utilizing remote monitoring and promoting behavioral changes. This study aims to evaluate the effectiveness of LYFE app intervention in improving outcomes for patients with CAD, specifically those with ACS or who have undergone percutaneous coronary intervention (PCI).
Methods: This pilot, single-center, real-world evidence study evaluates the effectiveness of the LYFE in CAD and/or post-PCI patients. The primary goal was to assess adherence to medication, physical exercise, diet, and well-being of the participants. Secondary outcomes included assessing vital changes and the incidence of major adverse cardiovascular events over 6 months.
Results: Among all participants, the majority were male (93.3%) with a mean age of 53.2±12.1 years. After implementing the LYFE app, 90% adhered to regular exercise, 79.3% to prescribed diet and 79.3% reported that they had no difficulty in remembering medication over 6 months. Additionally, notable improvements were observed in the well-being of the participants using the Dartmouth COOP questionnaire. Furthermore, the intervention significantly reduced SBP (-5.52 mmHg, p=0.038), and DBP (-2.63 mmHg, p=0.044) over 6-month follow-up. By the end of the study, 88.9% of the patients had their blood pressure under control. No cardiovascular death or major bleeding events were reported.
Conclusions: LYFE has the potential to enhance cardiovascular health and well-being in CAD and/or post-PCI patients.
Metrics
References
Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-23.
Sucato V, Coppola G, Manno G, Vadalà G, Novo G, Corrado E, et al. Coronary Artery Disease in south asian patients: cardiovascular risk factors, pathogenesis and treatments. Curr Probl Cardiol. 2023;48(8):101228.
Ralapanawa U, Sivakanesan R. Epidemiology and the magnitude of Coronary Artery Disease and Acute Coronary Syndrome: a narrative review. J Epidemiol Glob Health. 2021;11(2):169-77.
Prasad K. Current Status of primary, secondary, and tertiary prevention of Coronary Artery Disease. Int J Angiol Off Publ Int Coll Angiol Inc. 2021;30(3):177-86.
Khan SQ, Ludman PF. Percutaneous coronary intervention. Medicine (Baltimore). 2022;50(7):437-44.
Al-Arkee S, Mason J, Lane DA, Fabritz L, Chua W, Haque MS, et al. Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis. J Med Internet Res. 2021;23(5):e24190.
Baig MM, Gholam Hosseini H, Connolly MJ. Mobile healthcare applications: system design review, critical issues and challenges. Australas Phys Eng Sci Med. 2015;38(1):23-8.
Smith B, Magnani JW. New technologies, new disparities: The intersection of electronic health and digital health literacy. Int J Cardiol. 2019;292:280-82.
Guo Y, Yin F, Fan C, Wang Z. Gender difference in clinical outcomes of the patients with coronary artery disease after percutaneous coronary intervention. Medicine (Baltimore). 2018;97(30):e11644.
Sharma M, Ganguly NK. premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag. 2005;1(3):217-25.
Aggarwal P, Sinha SK, Marwah R, Nath RK, Pandit BN, Singh AP. Effect of Percutaneous Coronary Intervention on diastolic function in Coronary Artery Disease. J Cardiovasc Echography. 2021;31(2):73-6.
Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. Plos One. 2018;13(6):e0198144.
Notara V, Panagiotakos DB, Pitsavos CE. Secondary prevention of acute coronary syndrome. Socio-economic and lifestyle determinants: a literature review. Cent Eur J Public Health. 2014;22(3):175-82.
Kendir C, van den Akker M, Vos R, Metsemakers J. Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands. Eur J Gen Pract. 2018;24(1):45-50.
Afzal MR, Savona S, Mohamed O, Mohamed-Osman A, Kalbfleisch SJ. Hypertension and Arrhythmias. Heart Fail Clin. 2019;15(4):543-50.
Liu CH, Huang YC. Comparison of STEMI and NSTEMI patients in the emergency department. J Acute Med. 2011;1(1):1-4.
Ibanez B, James S, Agewall S, Antunes M.J, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77.
Sharma SP, Dahal K, Khatra J, Rosenfeld A, Lee J. Percutaneous coronary intervention vs coronary artery bypass grafting for left main coronary artery disease? A systematic review and meta-analysis of randomized controlled trials. Cardiovasc Ther. 2017;35(3):10.1111/1755-5922.12260.
Naganuma T, Chieffo A, Meliga E, Capodanno D, Park SJ, Onuma Y, et al. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. JACC Cardiovasc Interv. 2013;6(12):1242-29.
Schorr EN, Gepner AD, Dolansky MA, Forman D, Park L, Petersen K, et al. Harnessing mobile health technology for secondary cardiovascular disease prevention in older adults: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2021;14(5):e000103.
Jakob R, Harperink S, Rudolf AM, Fleisch E, Haug S, Mair JL, et al. Factors influencing adherence to mHealth apps for prevention or management of noncommunicable diseases: systematic review. J Med Internet Res. 2022;24(5):e35371.
Jiang J, Zhu Q, Zheng Y, Zhu Y, Li Y, Huo Y, et al. Perceptions and acceptance of mhealth in patients with cardiovascular diseases: a cross-sectional study. JMIR MHealth UHealth. 2019;7(2):e10117.
Gandhi S, Chen S, Hong L, Sun K, Gong E, Li C, et al. Effect of mobile health interventions on the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Can J Cardiol. 2017;33(2):219-31.
Lu X, Yang H, Xia X, Lu X, Lin J, Liu F, et al. Interactive mobile health intervention and blood pressure management in adults. Hypertension. 2019;74(3):697-704.
Pina IL, Di Palo KE, Brown MT, Choudhry NK, Cvengros J, Whalen D, et al. Medication adherence: importance, issues and policy: a policy statement from the American Heart Association. Prog Cardiovasc Dis. 2021;64:111-20.
Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, et al. Treatment adherence and risk of death after a myocardial infarction. Lancet Lond Engl. 1990;336(8714):542-45.
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2-year results from a prospective observational study. Lancet Lond Engl. 2013;382(9906):1714-22.
Armitage LC, Kassavou A, Sutton S. Do mobile device apps designed to support medication adherence demonstrate efficacy? A systematic review of randomized controlled trials, with meta-analysis. BMJ Open. 2020;10(1):e032045.
Pfaeffli Dale L, Whittaker R, Jiang Y, Stewart R, Rolleston A, Maddison R. Text message and internet support for coronary heart disease self-management: results from the Text4Heart randomized controlled trial. J Med Internet Res. 2015;17(10):e237.
Tian M, Ajay VS, Dunzhu D, Hameed SS, Li X, Liu Z, et al. A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard Trial) in Rural Tibet, China, and Haryana, India. Circulation. 2015;132(9):815-24.
Kaihara T, Intan-Goey V, Scherrenberg M, Falter M, Frederix I, Dendale P. Impact of activity trackers on secondary prevention in patients with coronary artery disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022;29(7):1047-56.
Marvel FA, Spaulding EM, Lee MA, Yang WE, Demo R, Ding J, et al. Digital health intervention in Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes. 2021;14(7):e007741.
Wita K, Kułach A, Sikora J, Fluder J, Nowalany-Kozielska E, Milewski K, et al. Managed care after Acute Myocardial Infarction (MC-AMI) reduces total mortality in 12-month follow-up-results from a Poland’s national health fund program of comprehensive Post-MI care-a population-wide analysis. J Clin Med. 2020;9(10):3178.
Cajita MI, Zheng Y, Kariuki JK, Vuckovic KM, Burke LE. mHealth technology and CVD risk reduction. Curr Atheroscler Rep. 2021;23(7):36.
Zhong W, Fu C, Xu L, Sun X, Wang S, He C, et al. Effects of home-based cardiac telerehabilitation programs in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):101.
Murphy AC, Meehan G, Koshy AN, Kunniardy P, Farouque O, Yudi MB. Efficacy of smartphone-based secondary preventive strategies in Coronary Artery Disease. Clin Med Insights Cardiol. 2020;14:1179546820927402.
Cruz-Cobo C, Bernal-Jiménez MÁ, Vázquez-García R, Santi-Cano MJ. Effectiveness of mHealth interventions in the control of lifestyle and cardiovascular risk factors in patients after a coronary event: systematic review and meta-analysis. JMIR MHealth UHealth. 2022;10(12):e39593.
Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary prevention of cardiovascular disease: a systematic review. BMC Cardiovasc Disord. 2018;8(1):25.
Helal SI, Murrells T, Grealish A, Evans CJ. Factors associated with depression and anxiety for community-dwelling patients with heart failure: a retrospective cohort study. J Cardiovasc Nurs. 2023;38(3):210.
Lakhani F, Racette SB, Park LK, Deych E, Williams D, McKenzie KM, et al. Prospective study of the impact of outpatient intensive cardiac rehabilitation on diet quality, health-related quality of life, and cardiovascular health indices. Am J Cardiol. 2023;192:60-6.
Downloads
Published
How to Cite
Issue
Section
